Thirteen different studies, which included the use of ImmuKnow(R) to assess immune cell function, will be presented at the annual American Transplant
Congress
COLUMBIA, Md., May 30 /PRNewswire/ -- On Saturday, May 31 through Tuesday, June 3, at the annual American Transplant Congress (ATC) in Toronto, Canada, a total of 13 presentations will either report specifically on studies of the use of the ImmuKnow assay or will include information on the use of this assay in monitoring kidney, liver, and heart transplant patients over time.
Since it was initially cleared as an in vitro diagnostic technique to
detect cell-mediated immunity (CMI) in adult patient populations undergoing
immunosuppressive therapy for organ transplantation, understanding of the
possible applications of the Cylex(TM) ImmuKnow assay (in clinical practice
and in the clinical research setting) has continued to expand. Selected
institutions are expected to issue their own detailed media information
about individual studies (highlighted in bold type below). However, the
full list of studies that is known to either focus on or include explicit
reference to use of the ImmuKnow assay for CMI is as follows:
Saturday, May 31, 2008
-- "Is infection in heart transplant patients related to low immune cell
function or low white blood cell count or both?" (B. Pavlovic
Surjancev, P. Lingam, N. Patel, et al.) -- poster presentation, 5:30
p.m. - 7:00 p.m. (Poster Session: Heart Transplantation I)
This study, from Loyola University Medical Center in Maywood, IL,
assesses relative values of cell-mediated immunity, white blood cell
count, and lymphocyte count in monitoring 26 heart transplant patients
of whom 15 had various infections.
-- "Sirolimus (SRL) blunts mitogen response at trough (C0) levels more
than cyclosporine (CSA) or tacrolimus (TAC) -- a saf
'/>"/>
| SOURCE Cylex, Incorporated Copyright©2008 PR Newswire. All rights reserved |